Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome With Major Depressive Disorder or Dysthymic Disorder.

Trial Profile

Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome With Major Depressive Disorder or Dysthymic Disorder.

Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Jul 2013

At a glance

  • Drugs Armodafinil (Primary)
  • Indications Hypersomnia
  • Focus Therapeutic Use
  • Sponsors Cephalon
  • Most Recent Events

    • 26 May 2010 Secondary endpoints of patient functioning and fatigue presented at the 163rd Annual Meeting of the American Psychiatric Association.
    • 29 Dec 2009 Results published in the Journal of Clinical Psychiatry.
    • 13 May 2009 Actual patient number (250) added as reported by ClinicalTrials.gov as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top